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Mitochondria have long been known to be the gatekeepers of cell fate. This is particularly so in the response to acute
ischaemia-reperfusion injury (IRI). Following an acute episode of sustained myocardial ischaemia, the opening of the
mitochondrial permeability transition pore (MPTP) in the first few minutes of reperfusion, mediates cell death. Preventing
MPTP opening at the onset of reperfusion using either pharmacological inhibitors [such as cyclosporin A (CsA) ] or genetic
ablation has been reported to reduce myocardial infarct (MI) size in animal models of acute IRI. Interestingly, the endogenous
cardioprotective intervention of ischaemic conditioning, in which the heart is protected against MI by applying cycles of brief
ischaemia and reperfusion to either the heart itself or a remote organ or tissue, appears to be mediated through the inhibition
of MPTP opening at reperfusion. Small proof-of-concept clinical studies have demonstrated the translatability of this
therapeutic approach to target MPTP opening using CsA in clinical settings of acute myocardial IRI. However, given that CsA
is a not a specific MPTP inhibitor, more novel and specific inhibitors of the MPTP need to be discovered – the molecular
identification of the MPTP should facilitate this. In this paper, we review the role of the MPTP as a target for cardioprotection,
the potential mechanisms underlying MPTP inhibition in the setting of ischaemic conditioning, and the translatability of MPTP
inhibition as a therapeutic approach in the clinical setting.
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Introduction
The mitochondria are crucial determinants of cardiomyocyte
fate following an episode of acute myocardial ischaemia-
reperfusion injury (IRI). In particular, reperfusing acutely
ischaemic myocardium induces the opening of the mito-
chondrial permeability transition pore (MPTP), an event that
mediates cardiomyocyte death by uncoupling oxidative
phosphorylation and causing mitochondrial swelling. Pre-
clinical animal studies (Hausenloy et al., 2002; 2003) and
initial proof-of-concept clinical trials (Piot et al., 2008; Chiari
et al., 2014; Hausenloy et al., 2014) have demonstrated that
the pharmacological inhibition of MPTP opening at the onset
of reperfusion can attenuate cardiomyocyte death and reduce
myocardial infarct (MI) size. The endogenous cardioprotec-
tive phenomenon of ischaemic conditioning, in which the
heart is protected against MI by subjecting it to brief cycles of
ischaemia and reperfusion, mediates its cardioprotective
effect by recruiting many signalling pathways and preventing
MPTP opening (Hausenloy et al., 2002; 2009a). In this paper,
we review the role of the MPTP as a target for ischaemic
conditioning, the potential mechanisms mediating MPTP
inhibition in the setting of ischaemic conditioning and the
translatability of MPTP inhibition as a therapeutic approach
in the clinical setting.
MPTP as a target for cardioprotection
The concept of a mitochondrial inner membrane pore
opening to induce a transition in mitochondrial permeability
was first proposed and characterized in seminal studies by
Haworth and Hunter in the late 1970s (Haworth and Hunter,
1979; Hunter and Haworth, 1979a,b). Despite intensive
investigation, the molecular identity of the MPTP is still
undefined, with transgenic animal studies excluding several
putative components including the adenine nucleotide trans-
locase (ANT) (Kokoszka et al., 2004), the voltage-dependent
anion channel (VDAC) (Baines et al., 2007), and more
recently the mitochondrial phosphate carrier (SLC25A3;
Kwong et al., 2014a,b). Conversely, mitochondrial cyclophi-
lin D (CypD) has been implicated as an important regulatory
component of the MPTP (Baines et al., 2005; Basso et al.,
2005), and most recently, the c-subunit of the ATP synthase
has been proposed to form the pore component of the MPTP
in the inner mitochondrial membrane (Bonora et al., 2013;
Giorgio et al., 2013; Alavian et al., 2014).
Pioneering studies by Crompton’s group in the late
1980s were the first to implicate the MPTP as a critical
determinant of cardiomyocyte death in the setting of acute
IRI showing that ATP depletion, mitochondrial calcium
overload, oxidative stress and phosphate levels were key
inducers of MPTP opening, which could be inhibited by
cyclosporin A (CsA; Crompton et al., 1987; 1988). Griffiths
and Halestrap (1995) then made the crucial discovery that
the MPTP remained closed during the index ischaemic
period, and only opened in the first 2–3 min of reperfusion.
We later confirmed that MPTP opening occurred primarily
at the onset of reperfusion by showing that administering
CsA solely at the onset of myocardial reperfusion limited MI
size (Hausenloy et al., 2002). Crucially, we found that the
cardioprotective effects of MPTP inhibition were completely
lost if the MPTP inhibitor was administered after the first
15 min of myocardial reperfusion had elapsed (Hausenloy
et al., 2003), emphasizing the importance of intervening in
the first few minutes to prevent MPTP opening. This has
defined a critical time window for employing MPTP inhibi-
tion and targeting myocardial reperfusion injury as a car-
dioprotective strategy, such that a therapeutic strategy
designed to target reperfusion injury has to be administered
prior to or at the immediate onset of reperfusion – this criti-
cal timing of the therapeutic intervention has had impor-
tant implications in the translation of cardioprotection into
the clinical setting (Hausenloy et al., 2011; 2013; Ovize
et al., 2010).
Tables of Links
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MPTP as target for ischaemic
conditioning
Inhibition of MPTP opening at the onset of reperfusion has
been shown to underlie the cardioprotection elicited by the
endogenous phenomenon of ‘ischaemic conditioning’, a term
encompassing the various approaches to myocardial ‘condi-
tioning’ where the heart is rendered resistant to acute IRI by
subjecting it to one or more cycles of brief ischaemia and
reperfusion (Murry et al., 1986; Hausenloy, 2013). Experimen-
tal studies have demonstrated that MPTP opening is inhibited
at the onset of reperfusion in hearts subjected to either ischae-
mic preconditioning (IPC, in which the heart is subjected to
one of more brief cycles of ischaemia and reperfusion prior to
the index ischaemia) (Murry et al., 1986; Hausenloy et al.,
2002; 2004; Javadov et al., 2003) or ischaemic postcondition-
ing (IPost, in which myocardial reperfusion following the
index ischaemic event is interrupted by several short-lived
episodes of myocardial ischaemia) (Zhao et al., 2003; Argaud
et al., 2005). Whether MPTP inhibition underlies the cardio-
protection elicited by remote ischaemic conditioning (RIC)
(Przyklenk et al., 1993; Hausenloy and Yellon, 2008), whereby
the cardioprotective stimulus is applied to an organ or tissue
away from the heart is not known.
MPTP as a target for IPC
In 2001, Xu et al. (2001) first proposed that the MPTP may be
a potential target of calcium-induced preconditioning in
isolated cardiomyocytes, although no direct experimental
evidence of MPTP inhibition was provided. We then demon-
strated that the preconditioning mimetic, diazoxide, a pur-
ported opener of the mitochondrial ATP-sensitive potassium
channel (MitoKATP) channel, inhibits calcium-induced MPTP
opening in adult rat cardiac mitochondria (Hausenloy et al.,
2002). Subsequent studies have confirmed MPTP inhibition
at the time of reperfusion in several different settings of
preconditioning (Javadov et al., 2003; Argaud et al., 2004;
Hausenloy et al., 2004; Juhaszova et al., 2004).
MPTP as a target for IPost
Experimental studies have also linked IPost cardioprotection
to the inhibition of MPTP opening at the onset of reperfu-
sion. In 2005, Ovize’s research group (Argaud et al., 2005)
were the first to demonstrate calcium-induced MPTP inhibi-
tion in mitochondria isolated from IPost-treated rabbit hearts
(Bopassa et al., 2006; Fang et al., 2008). Importantly, our
research group (Lim et al., 2007) have found that mice defi-
cient in mitochondrial CypD were resistant to the infarct-
limiting effects of IPost confirming the importance of CypD
in MPTP.
MPTP as a target for RIC
The mechanism through which the cardioprotective signal
applied to an organ or tissue remote from the heart activates
pro-survival signalling pathways in the heart is not clear.
Wang et al. (2008) have shown that RIC in vivo using limb
preconditioning generated a dialysate, which protected naïve
perfused rabbit hearts against the myocardial IRI in terms of
preserved outer mitochondrial membrane (OMM) integrity
and maintained mitochondrial function. However, no studies
have investigated directly whether the MPTP is a target for
cardioprotection in the setting of RIC.
How does ischaemic conditioning
inhibit MPTP opening
The actual mechanism through which the cardioprotective
signal elicited by ischaemic conditioning mediates its inhibi-
tory effect on MPTP opening at the time of myocardial rep-
erfusion is not clear. A number of potential mechanisms have
been proposed, and these can be broadly divided into two
different categories (which may not be mutually exclusive)
(as summarised in Figure 1):
(1) Passive pathway – ischaemic conditioning modulates
factors such as cellular energy status, mitochondrial
calcium and phosphate accumulation, oxidative stress,
and intracellular pH changes, which are known to affect
MPTP opening susceptibility (Griffiths and Halestrap,
1995; Hausenloy and Yellon, 2003; Halestrap and
Richardson, 2014);
(2) Active pathway – ischaemic conditioning activates a
signalling pathway, which then modifies MPTP opening
susceptibility by either interacting with putative compo-
nents of the MPTP, or by modulating the same factors
alluded to in the ‘passive pathway’.
Passive pathway of MPTP inhibition in
ischaemic conditioning
Preserving mitochondrial energy during acute IRI. The cellular
de-energization and depletion of ATP induced by acute pro-
longed myocardial ischaemia contributes to the opening of
the MPTP at the time of reperfusion. Murry et al. (1986) first
proposed in their seminal IPC study that the preservation of
myocardial ATP levels during ischaemia was critical to IPC
cardioprotection. This mechanism was confirmed in several
experimental studies, although linking this effect to MPTP
inhibition has not been shown (Murry et al., 1990; Kobara
et al., 1996; Fryer et al., 2000; Laclau et al., 2001).
Attenuating mitochondrial calcium overload during acute
IRI. Intracellular acidosis during acute myocardial ischae-
mia results in intracellular calcium overload and subsequent
mitochondrial calcium accumulation, which is exacerbated
at the time of reperfusion and results in MPTP opening
(Ruiz-Meana et al., 2006). It has been suggested that by
opening the ATP-dependent mitochondrial potassium
channel (MitoKATP), IPC may reduce mitochondrial calcium
overload during ischaemia and inhibit MPTP opening at rep-
erfusion (Murata et al., 2001), although this mechanism has
been questioned (Ardehali and O’Rourke, 2005; Hanley and
Daut, 2005). Recent experimental studies have suggested that
oxidative stress and the restoration of physiological pH may
be more important inducers of MPTP opening at the onset of
reperfusion than mitochondrial calcium overload (Kim et al.,
2006; Ruiz-Meana et al., 2006). Furthermore, genetic ablation
of the recently discovered mitochondrial calcium uniporter
was found to reduce the sensitivity to calcium-induced MPTP
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opening, but did not have any effect on the susceptibility of
the heart to acute IRI, again questioning the role of mito-
chondrial calcium overload as a trigger of MPTP opening at
the time of reperfusion (Pan et al., 2013).
Attenuating oxidative stress production during acute IRI. Oxida-
tive stress generated during acute myocardial ischaemia may
prime the MPTP to open at the time of reperfusion (Robin
et al., 2007), and the production of oxidative stress from the
re-energized electron transport chain in the first few minutes
of reperfusion is a major factor for inducing MPTP opening.
Experimental studies have shown that both IPC and IPost
attenuate the production of oxidative stress at the time of
reperfusion (Crestanello et al., 1996; Zhao et al., 2003; Sun
et al., 2005; Clarke et al., 2008), although this effect has not
yet been linked to MPTP inhibition. The actual mechanism
through which IPC and IPost actually attenuate oxidative
stress at the time of reperfusion is not clear. Halestrap’s group
(Pasdois et al., 2011) has postulated that IPC preserves the
integrity of the OMM, thereby preventing loss of cytochrome
c into the cytosol, thereby attenuating the production of
oxidative stress and MPTP opening at reperfusion (Pasdois
et al., 2011). More recently, Murphy’s group (Chouchani
et al., 2014) has shown that ischaemia results in the myocar-
dial accumulation of the mitochondrial complex II substrate,
succinate, which at the onset of reperfusion then provides a
substrate load to complex II, which via reverse electron trans-
port feeding to complex I, generates the oxidative stress
observed in the first few minutes of reperfusion. Whether
IPC confers its cardioprotective effect by attenuating the
ischaemia-induced accumulation of succinate, and IPost does
so by antagonizing the production of oxidative stress
from complex I at the onset of reperfusion, remains to be
investigated.
Delaying intracellular pH correction at reperfusion. During the
index ischaemia, the intracellular acidosis keeps the MPTP
closed, and it is only in the first few minutes of reperfusion
with the rapid restoration of intracellular pH that permits the
MPTP to open at the onset of reperfusion (Yellon and
Figure 1
Reperfusion signalling pathways underlying ischaemic conditioning. The diagram provides a simplified scheme of some of the potential
reperfusion signalling pathways linking ischaemic conditioning to the MPTP. These can be categorized into: (i) ‘Active MPTP inhibition’ (light blue
shaded box): this includes those mechanistic pathways in which a signal transduction pathway has been implicated. This begins at the
cardiomyocyte plasma membrane with the activation of the G-protein coupled or cytokine receptor by autocoids such as adenosine, bradykinin
or opioids, which result in the recruitment of complex signal transduction pathways many of which terminate on the mitochondria, and involve
in some cases the translocation of protein kinases to the mitochondria. For the sake of clarity only the components of the RISK (PI3K-Akt and
MEK1/2-Erk1/2), SAFE (JAK-STAT) and the PKG pathways are shown on this diagram. These reperfusion salvage pathways have been shown to
activate downstream mediators such as eNOS, GSK-3β, HKII, PKC-ε, the mitochondrial ATP-dependent potassium channel (KATP), which then
mediate the inhibitory effect on MPTP opening. (ii) ‘Passive MPTP inhibition’ (purple shaded box): this includes mechanisms that result in MPTP
inhibition as an indirect effect of ischaemic conditioning on factors that are known to induce MPTP opening at the time of myocardial reperfusion
such as attenuating detrimental ROS production, preserving ATP levels, delaying pH correction at reperfusion, and reducing mitochondrial calcium
and phosphate overload. Clearly, these two categories are not mutually exclusive and there may overlap, for example, both PKG and PI3K-Akt have
been reported to influence intracellular calcium regulation by promoting the uptake of calcium via SERCA into the sarcoplasmic reticulum
[modified from Hausenloy et al., 2009b).
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Hausenloy, 2007). It has been proposed that both IPC and
IPost may delay or modify the changes in intracellular pH at
the onset of reperfusion such that there is a delay in the
restoration of physiological pH thereby keeping the MPTP
closed for the first few minutes of reperfusion (Cohen et al.,
2007). Early studies had reported that IPC may attenuate the
intracellular acidosis generated during ischaemia by either
reducing myocardial glycogen depletion during index ischae-
mia (Asimakis et al., 1992; Wolfe et al., 1993) or by inhibiting
the sodium ion–hydrogen ion exchanger at reperfusion (Xiao
and Allen, 1999; 2000). Hori et al. (1991) first demonstrated,
in 1991, that intermittent reperfusion induced transient aci-
dosis and ameliorated myocardial stunning. Subsequent
studies have confirmed that IPost delays the restoration of
physiological pH at reperfusion, which prevents MPTP
opening thereby allowing the activation of pro-survival
kinases such as Akt and ERK1/2 (the pH hypothesis) (Cohen
et al., 2007; Fujita et al., 2007).
Active pathways of MPTP inhibition in
ischaemic conditioning
MitoKATP channel and the MPTP. MitoKATP, a mediator of IPC,
has been reported to exert cardioprotection by reducing cyto-
solic and mitochondrial calcium overload (Garlid et al., 1997;
Liu et al., 1998; Garlid, 2000; Murata et al., 2001). More
recently, Garlid has proposed a more direct mechanistic
pathway to link MitoKATP channel opening with MPTP inhi-
bition through PKG, mitochondrial PKC-ε, the MitoKATP
channel, matrix alkalinization, superoxide and hydrogen per-
oxide production from complex I (Costa et al., 2005; 2006;
Jaburek et al., 2006; Costa and Garlid, 2008). Several issues
remain unclear with this particular mechanistic pathway:
whether mitochondria actually contain PKC-ε and whether
there are two pools of this protein are not clear; how cytosolic
PKG is able to activate mitochondrial PKC-ε is not known;
how PKC-ε inhibits MPTP opening is not clear; and finally
whether this mechanistic pathway is actually operational
in the first few minutes of reperfusion has not been
demonstrated.
Reperfusion injury salvage kinase (RISK) and survival activation
factor enhancement (SAFE) pathways and the MPTP. It is well-
established that the acute activation of cardioprotective
kinase pathways (such as the RISK and SAFE pathways) at the
onset of myocardial reperfusion, can limit MI size (Hausenloy
and Yellon, 2004; 2007; Lecour, 2009; Hausenloy et al., 2011).
Crucially, ischaemic conditioning has been reported to
recruit these salvage kinase pathways at the onset of reperfu-
sion and there is evidence linking these pathways to MPTP
inhibition (Hausenloy et al., 2005; Breivik et al., 2011).
RISK pathway and the MPTP. All three forms of ischaemic
conditioning (IPC, IPost and RIC) have been linked to the
activation of the RISK pathway and in the cases of IPC and
IPost the activation of this salvage kinase cascade has been
shown to inhibit MPTP opening (Hausenloy et al., 2005;
Bopassa et al., 2006; Davidson et al., 2006; Breivik et al.,
2011). Experimental data have suggested that the salvage
kinases of the RISK pathway such as Akt (Bijur and Jope,
2003), ERK1/2 (Baines et al., 2002) and PKG (Costa et al.,
2005) may translocate to mitochondria, and in some cases,
the mitochondrial translocation has been linked to MPTP
inhibition, although the actual mechanisms are not known.
The link between these cardioprotective kinases translocating
to mitochondria and MPTP inhibition has been questioned,
with the proposal that IPC inhibits MPTP opening by attenu-
ating oxidative stress (Clarke et al., 2008). The mechanism
through which RISK pathway mediates its inhibitory effect
on MPTP opening is unclear although it may do so through
the activation of downstream mediators such as PKG, glyco-
gen synthase kinase (GSK)-3β or hexokinase II (HKII).
PKG and the MPTP. The activation of the Akt component of
the RISK pathway is known to recruit the eNOS-NO-sGC-
cGMP-PKG pathway and through this cascade (Garlid et al.,
2004; Garcia-Dorado et al., 2009) the RISK pathway may
inhibit MPTP opening. This pathway appears to be mediated
through the translocation of PKG to the OMMwhere it inhib-
its MPTP opening (see MitoKATP channel and the MPTP).
GSK-3β and the MPTP. An important downstream target of
the Akt and Erk1/2 components of the RISK pathway is GSK-
3β, a protein kinase, which regulates a variety of cellular
processes including apoptosis, growth and metabolism
(Cohen and Frame, 2001). The phosphorylation and inacti-
vation of GSK-3β has been linked to cardioprotection by IPC
and IPost (Tong et al., 2002; Gomez et al., 2008), although not
all studies have been in agreement (Nishino et al., 2008).
Sollott’s group (Juhaszova et al., 2004) provided comprehen-
sive in vitro evidence suggesting that the phosphorylation and
inactivation of mitochondrial GSK-3β with MPTP inhibition
was the underlying mechanism for a diverse array of cardio-
protective strategies. However, the mechanism through
which mitochondrial GSK-3β inhibition actually mediates
MPTP inhibition is unclear. Nishihara et al. (2007) have
reported that GSK-3β associated with ANT in IPC-treated
hearts, but the ANT is no longer considered to be an essential
component of the MPTP (Kokoszka et al., 2004). A more
recent study has suggested that GSK-3β inhibition, allows the
dephosphorylation of the OMM protein, VDAC, which pre-
vents the entry of adenine nucleotides into mitochondria,
which would be expected to facilitate mitochondrial depo-
larization and reduce mitochondrial calcium accumulation
and reactive oxygen species (ROS) production during myo-
cardial ischaemia thereby preventing MPTP opening at the
time of reperfusion (Das et al., 2008). Whether this mecha-
nism actually operates in the setting of IPC and IPost remains
to be investigated.
HKII and the MPTP. Another downstream mediator of the
Akt component of the RISK pathway is the glycolytic enzyme
HKII, the mitochondrial translocation of which has been
implicated in IPC cardioprotection (Smeele et al., 2011), as
reviewed in Zuurbier et al. (2009). A variety of different
mechanisms have been proposed to explain the cardioprotec-
tive effect of mitochondrial HK II including the maintenance
of OMM integrity during acute IRI (stabilizing the mitochon-
drial membrane potential and preventing the release of
cytochrome c), attenuating ROS production, improving
glucose-induced insulin release, preventing acidosis through
enhanced coupling of glycolysis and glucose oxidation, and
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inhibition of fatty acid oxidation (see Nederlof et al., 2014).
Again the interplay between HK II and MPTP inhibition in
the context of IPC or IPost remains unclear.
SAFE pathway and the MPTP. Recruitment of the SAFE
pathway at the time of reperfusion, which includes TNF-α
and STAT-3, has been associated with both IPC and IPost
cardioprotection (Lacerda et al., 2009; Lecour, 2009). The acti-
vation of the SAFE pathway at the onset of reperfusion has
also been linked to MPTP inhibition (Smith et al., 2006;
Boengler et al., 2010), although the mechanism for this effect
is not clear. Recent experimental data have suggested that
STAT3 may actually reside in the mitochondria (Wegrzyn
et al., 2009), but the mechanism through which it inhibits
MPTP opening is not known. Again, whether this pathway
operates at reperfusion in the setting of IPC or IPost has not
been investigated.
Mitochondrial morphology and the MPTP. Mitochondria are
dynamic structures capable of changing their morphology by
undergoing either fusion to generate an elongated phenotype
[regulated by the mitochondrial-fusion proteins (mitofusins
and optic atrophy 1, OPA1) ] or fission to form fragmented
mitochondria [regulated by the mitochondrial-fission pro-
teins (dynamin-related protein 1, Drp1; human fission
protein 1) ] (Ong and Hausenloy, 2010; Hall and Hausenloy,
2012; Ong et al., 2013; Hall et al., 2014). Recent experimental
data suggest that mitochondria undergo fission and MPTP
opening in response to acute IRI, and genetic or pharmaco-
logical inhibition of mitochondrial fission inhibits MPTP
opening and attenuate cell death (Ong et al., 2010). This
initial data suggested a link between mitochondrial morphol-
ogy and MPTP opening susceptibility, with inhibiting mito-
chondrial fission induced by acute IRI preventing MPTP
opening at reperfusion.
Interestingly, some of the cardioprotective kinases, which
have been linked to MPTP inhibition in the setting of ischae-
mic conditioning such as PKA (Sanada et al., 2004) and Akt,
have been reported to modulate mitochondrial morphology
through the phosphorylation of Drp1 (Chang and
Blackstone, 2007; Cribbs and Strack, 2007) and OPA1 (Parra
et al., 2014) respectively. A recent experimental study has
shown that pharmacological preconditioning with nitrites
inhibits mitochondrial fission through PKA-induced phos-
phorylation and inhibition of Drp1 (Kamga et al., 2014). Fur-
thermore, Akt has also been recently shown to modulate
mitochondrial morphology, but whether it does so in the
context of ischaemic conditioning is not known (Ong et al.,
2014; Parra et al., 2014). Finally, whether ischaemic condi-
tioning protects the heart against acute IRI by inhibiting
mitochondrial fission and MPTP inhibition has not been
investigated.
Aldehyde dehydrogenase-2 and the MPTP. Mitochondrial alde-
hyde dehydrogenase 2 (ALDH2) has also been identified as a
key enzyme involved in cytoprotection in the heart (Chen
et al., 2008; Budas et al., 2009; 2010; Gong et al., 2013).
ALDH2 is one of the 19 members of the ALDH gene family,
which mediates the oxidation and detoxification of reactive
aldehydes in different organs and cell types (Vasiliou and
Nebert, 2005). ALDH2 is encoded in the nucleus and
imported into the mitochondrial matrix, because of a
17-amino acid N-terminal mitochondrial localization
sequence (Vasiliou and Nebert, 2005). PKC-ε has been shown
to phosphorylate ALDH2 in vitro, resulting in an increase in
ALDH2 catalytic activity (Chen et al., 2008). At least two
phosphorylation sites have been identified by MS, including
Thr185 and Thr412 and possibly, Ser279 (Chen et al., 2008). Pre-
treatment with the ALDH2 agonist, N-(1,3-benzodioxol-5-
ylmethyl)-2,6-dichlorobenzamide (Alda-1) in an in vivo rat
model of acute MI reduced cardiac damage (Chen et al.,
2008). Ethanol preconditioning has also been demonstrated
to promote activation and translocation of PKC-ε into cardiac
mitochondria where it interacts with ALDH2 (Budas et al.,
2010). ALDH2 mediates detoxification of reactive aldehydes
and bioactivation of nitroglycerin (see Budas et al., 2009).
Upregulation of mitochondrial ALDH2 activity can also
inhibit MPTP opening and thus induce cardioprotective out-
comes (Li et al., 2010), although the exact mechanism
remains unclear.
Translatability of MPTP inhibition as a
therapeutic approach
The majority of experimental studies have reported MPTP
inhibition using CsA to be an effective cardioprotective strat-
egy. However, there have been some neutral studies using in
vivo MI models in rats (De et al., 2013) and pigs (Karlsson
et al., 2010). The reason for these discrepant results is not
clear (Hausenloy et al., 2012), although there are several
potential factors including: (i) the presence of other types of
cell death, such as apoptosis and programmed cell necrosis
(or necroptosis) in the myocardium after acute IRI (Luedde
et al., 2014) – in addition whether these other forms of cell
death are attenuated by ischaemic conditioning needs to be
determined; (ii) MPTP opening is not the only contributor to
necrotic cell death following acute IRI (Garcia-Dorado et al.,
1997; Ruiz-Meana et al., 2009); and (iii) MPTP opening may
not be a target for cardioprotection following relatively short
episodes of myocardial ischaemia (Ruiz-Meana et al., 2011).
MPTP as a therapeutic target in
co-morbid conditions
Given the potential confounding effects of factors such as
age, diabetes, left ventricular (LV) hypertension, on cardio-
protection (Ferdinandy et al., 2007; 2014), it is important to
determine whether MPTP inhibition using CsA is effective in
these settings. In this regard, Huhn et al. (2010) have reported
that the pre-diabetic Zucker obese rat was resistant to the
MI-limiting effects of CsA administered at the onset of reper-
fusion. In contrast, CsA-cardioprotection was preserved in
the aged murine heart subjected to acute IRI (Peart
et al., 2014), suggesting that the modulation of CsA-
cardioprotection may depend on the particular confounding
factor.
MPTP inhibition as a therapeutic strategy in
the clinical setting
Acute myocardial infarction. The first study to investigate the
MPTP as a therapeutic target in the clinical setting of acute
BJPConditioning the heart and the MPTP
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MI, was by Piot et al. (Piot et al., 2008), who randomized 58
patients presenting with an acute ST segment elevation myo-
cardial infarction (STEMI) to receive either a single intrave-
nous bolus of either CsA (2.5 mg/kg) or placebo 10 min prior
to primary percutaneous coronary intervention (PPCI). In
those patients who received CsA therapy, MI size was reduced
by 40% when compared to placebo control. In a follow-up
study, it was demonstrated that MI size was reduced and there
was less adverse LV remodelling on cardiac MRI scans
performed at 5 days and 6 months (Mewton et al., 2010).
However, in STEMI patients treated by thrombolytic therapy,
CsA did not reduce MI size (Ghaffari et al., 2013). The reason
for this discrepant finding is not clear, although thrombolytic
therapy by inducing gradual reperfusion may reduce the
magnitude of myocardial reperfusion injury.
The ongoing CYCLosporinE A in Reperfused Acute Myo-
cardial Infarction (CYCLE) (http://www.ClinicalTrials.gov
NCT01650662) and Cyclosporine and Prognosis in Acute
Myocardial Infarction Patients (CIRCUS) (http://www
.ClinicalTrials.gov NCT01502774) multi-centre randomized
clinical trials are currently investigating CsA therapy in PPCI-
treated STEMI patients.
Cardiac bypass surgery. Coronary revascularization by coro-
nary artery bypass graft (CABG) surgery, subjects the heart to
acute global IRI as the heart is put onto and taken off cardio-
pulmonary bypass. The extent of perioperative myocardial
injury (PMI) can be quantified by measuring the release into
blood of cardiac enzymes, such as creatine kinase and Tro-
ponin T or I, the release of which has been linked to worse
clinical outcomes. We have recently found that administer-
ing a single dose of CsA prior to CABG surgery reduced the
extent of PMI in CABG surgery patients (Hausenloy et al.,
2014). Another study has shown beneficial effects of CsA in
patients undergoing aortic valve surgery (Chiari et al., 2014).
Need for more specific
MPTP inhibitors
Although the discovery that MPTP opening could be inhib-
ited by targeting CypD using CsA has allowed us to investi-
gate the role of the MPTP as a mediator of acute IRI, CsA is
not without its problems (see Hausenloy et al., 2012). The
main concern is the specificity of CsA for the MPTP, given
that it inhibits other cyclophilins and also suppresses activity
of the phosphatase, calcineurin. In this regard, experimental
animal studies have reported cardioprotective effects with
CsA through mechanisms independent of MPTP inhibition
and instead mediated by calcineurin inhibition (Weinbrenner
et al., 1998; Cereghetti et al., 2008), cell volume regulation or
cyclophilin A inhibition. As such, more novel and specific
MPTP inhibitors need to be discovered if MPTP inhibition is
going to be widely used as a therapeutic approach for cardio-
protection. Knowing the identity, i.e., the components, of the
MPTP should facilitate this process.
Summary and conclusions
The opening of the MPTP at the onset of myocardial reper-
fusion is a critical determinant of myocardial reperfusion
injury. Although the mechanism(s) underlying cardioprotec-
tion by ischaemic conditioning remains unclear, evidence
suggests that it prevents MPTP opening at the reperfusion by
modulating factors known to MPTP opening at this time,
such as cellular energetic status, mitochondrial Ca2+ overload-
ing, ROS production, and rapid pH correction either directly
or indirectly via known cardioprotective signalling pathways.
The identification of the molecular pore of the MPTP should
provide further insight into unravelling the signalling
pathway involved in inhibition of the MPTP and further
enhance the translatability of MPTP inhibition to the clinical
setting.
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